Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - IntelGenx Corp. (IGXT.OB-OTC: BB) |
|
|
“Our focus is on oral drug delivery. Our platform technologies include systems for controlled release and immediate release dosage forms. Our controlled-release technology is based on layered tablets that consist of a non-erodible layer containing the active drug and one or more erodible cover layers. Upon contact of the tablet with the gastro-intestinal fluid, the cover layers erode at a pre-determined rate. This “controlled erosion” controls the release of an active drug from the...” - Horst G. Zerbe, Ph.D. (IGXT) (Interview published July 25, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
IntelGenx Corp. Welcomes New Chief Financial
Officer, Paul Simmons
SAINT LAURENT, QUEBEC--(MARKET WIRE)--Sep 5, 2008 -- IntelGenx
Technologies Corp. (Toronto:IGX.TO
- News)(OTC
BB:IGXT.OB -
News)("IntelGenx")
- Management of IntelGenx welcomes Paul Simmons as Chief
Financial Officer, effective September 1, 2008. A financial
executive with more than 20 years of delivering fiscal gains and
corporate growth worldwide, his expertise is in assisting
international corporations to improved profitability. Paul has
held CFO and VP-Finance positions with several manufacturers in
agricultural machinery, hearing aids, and classic English
knitwear.
"We welcome Paul to the IntelGenx Executive team and Canada. His
international background in corporate finance, business
expansion, mergers and acquisitions, process optimization and
strategic alliances will be a significant contribution as we
take this company to the next stages of success," said IntelGenx
President and CEO, Dr. Horst G. Zerbe.
Added Paul Simmons, "This is an extremely exciting time to join IntelGenx, as it makes the significant move from pure R&D operation to delivering product - our first launch is scheduled for Q4 2008. I look forward to playing a part in strengthening the company's financial position, and contributing to corporate development and strategies." About Paul Simmons Paul brings significant international credentials to the finance function with an Association of Financial Controllers and Administration (AFCA) certification and a designation with the Association of Accounting Technicians (MAAT). He is well versed in U.S. Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS). He has led the transformation from one application to the other in several organizations based on the commercial activities and best practices required for the company in the country of operation. Most recently he was employed within the CLAAS Group (2003 - 08), initially based at Group HQ in Germany as Head of Corporate Controlling until August 2005, and then seconded to the baler manufacturing subsidiary (Usines CLAAS France) where he implemented a successful turnaround - following many years of continuous losses. In September 2006 Paul was seconded to French subsidiary Renault Agriculture to restructure and integrate the newly acquired Tractor Manufacturing Division into the CLAAS Group. About IntelGenx Corp. IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at www.intelgenx.com. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact: Contacts: IntelGenx Corp. Dr. Horst G. Zerbe President and CEO (514) 331-7440x201 Email: horst@IntelGenx.com Website: http://www.intelgenx.com Source: IntelGenx Corp.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.